CareDx, Inc. (NASDAQ:CDNA - Get Free Report) Director George Bickerstaff sold 20,000 shares of the business's stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $46.28, for a total value of $925,600.00. Following the sale, the director directly owned 134,061 shares in the company, valued at approximately $6,204,343.08. The trade was a 12.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
CareDx Stock Down 1.5%
CDNA traded down $0.69 during trading on Thursday, reaching $44.81. The stock had a trading volume of 789,941 shares, compared to its average volume of 838,168. The stock has a 50 day moving average of $30.09 and a two-hundred day moving average of $23.18. The firm has a market capitalization of $2.32 billion, a price-to-earnings ratio of 21.65 and a beta of 2.39. CareDx, Inc. has a 1-year low of $11.26 and a 1-year high of $49.76.
CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.37 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.14. CareDx had a return on equity of 2.87% and a net margin of 24.23%.The company had revenue of $131.95 million for the quarter, compared to the consensus estimate of $114.05 million. During the same quarter in the previous year, the business earned ($0.16) EPS. The company's quarterly revenue was up 52.2% compared to the same quarter last year. On average, research analysts forecast that CareDx, Inc. will post 0.22 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
CDNA has been the subject of several recent research reports. HC Wainwright reissued a "neutral" rating and set a $46.00 target price on shares of CareDx in a research note on Friday, July 31st. William Blair raised CareDx to a "hold" rating in a report on Thursday, July 16th. Craig Hallum upgraded CareDx from a "hold" rating to a "buy" rating and set a $64.00 price objective for the company in a research report on Monday. Weiss Ratings raised CareDx from a "sell (d)" rating to a "sell (d+)" rating in a research note on Thursday, July 30th. Finally, BTIG Research lifted their target price on CareDx from $45.00 to $60.00 and gave the stock a "buy" rating in a report on Thursday. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, CareDx currently has a consensus rating of "Hold" and an average price target of $47.75.
View Our Latest Stock Analysis on CareDx
Institutional Investors Weigh In On CareDx
A number of institutional investors have recently bought and sold shares of CDNA. Quarry LP purchased a new position in CareDx during the fourth quarter valued at approximately $25,000. Meeder Asset Management Inc. acquired a new stake in shares of CareDx during the 4th quarter valued at $79,000. Quantbot Technologies LP purchased a new position in shares of CareDx during the 3rd quarter valued at $89,000. CWM LLC increased its stake in shares of CareDx by 119.1% in the fourth quarter. CWM LLC now owns 7,407 shares of the company's stock worth $140,000 after acquiring an additional 4,026 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of CareDx by 120.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company's stock worth $149,000 after acquiring an additional 4,160 shares in the last quarter.
About CareDx
(
Get Free Report)
CareDx, Inc NASDAQ: CDNA is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.
The company's core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
